P

Paratek Pharmaceuticals Inc
F:N4CN

Watchlist Manager
Paratek Pharmaceuticals Inc
F:N4CN
Watchlist
Price: 2.024 EUR
Market Cap: 115.9m EUR

Operating Margin
Paratek Pharmaceuticals Inc

-25.2%
Current
-87%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-25.2%
=
Operating Profit
-44.5m
/
Revenue
177m

Operating Margin Across Competitors

No Stocks Found

Paratek Pharmaceuticals Inc
Glance View

Market Cap
115.9m EUR
Industry
Pharmaceuticals

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.

N4CN Intrinsic Value
Not Available
P
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-25.2%
=
Operating Profit
-44.5m
/
Revenue
177m
What is the Operating Margin of Paratek Pharmaceuticals Inc?

Based on Paratek Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -25.2%.

Back to Top